Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I21HX003116-01A1 |
| Title: | Assessment of cardiotoxicity in Immunity Checkpoint Blockers and other cancer therapies |
| Principal Investigator: | Mary S. Vaughan-Sarrazin |
| Location: | Iowa City, IA |
| Congressional District Code: | 2 |
| Research Service: | Health Services R&D |
| Project Period: | September 2020 - February 2022 |
| FY 2021 Funding Amount: | $128,691 |
| Total Award Amount (all years): |
$200,000 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Background: Lung cancer is a leading cause of death from cancer death worldwide, and non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Advances in NSCLC treatment using tyrosine kinase inhibitors (TKI) and immunity checkpoint blockers (ICB) have led to improved survival. However, there is a growing concern that cardiotoxicity associated with novel cancer therapies may lead to premature morbidity among survivors. Unfortunately, heart damage due to cardiotoxicity is oft... |